Premium
An Indian biopharmaceutical company that counts private equity firm TPG as an investor will absorb a local drugmaker’s contract development and manufacturing organisation (CDMO) and soft gelatin business and list on stock exchanges. The multi-stage transaction will involve Stelis Biopharma Ltd, which secured $195 million from TPG Growth and other investors ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
